Boothbay Fund Management, LLC Biomarin Pharmaceutical Inc Transaction History

Boothbay Fund Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $1.67 Million - $2.23 Million	19,019 Added 281.26%	25,781 $2.51 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $157,085 - $210,850	1,941 Added 40.26%	6,762 $699,000
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $603,300 - $711,830	-7,343 Reduced 60.37%	4,821 $409,000
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $431,310 - $524,052	6,034 Added 98.43%	12,164 $1.01 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $295,114 - $368,257	-3,973 Reduced 39.32%	6,130 $473,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $724,587 - $924,121	10,103 New	10,103 $893,000
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $917,597 - $1.03 Million	-12,152 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $908,118 - $1.1 Million	12,152 New	12,152 $918,000
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $634,809 - $991,275	-7,980 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $569,532 - $772,863	7,980 New	7,980 $674,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.